Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Press Releases
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-12-05 am EST
1422.20 GBX   -0.13%
10:03aGSK plc - Jemperli RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer
AQ
07:18aGSK : Deutsche Bank sticks Neutral
MD
06:38aBank of America Downgrades GSK To Underperform From Neutral With Lower PT
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société GSK PLC
10:03aGSK plc - Jemperli RUBY phase III trial met its primary endpoint in a planned interim a..
AQ
12/02Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned inter..
AQ
12/02Gsk : European Medicines Agency accepts marketing authorisation application for momelotini..
PU
12/02Gsk : European Medicines Agency accepts marketing authorisation application for momelotini..
PU
11/30GSK plc - New global survey reveals opportunities to address organ damage risk with peo..
AQ
11/30GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisatio..
AQ
11/29Gsk : New global survey reveals opportunities to address organ damage risk with people liv..
PU
11/23GSK provides an update on Blenrep US marketing authorisation
AQ
11/23GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisatio..
AQ
11/15Gsk : tops Access to Medicine Index (ATMI) for eighth consecutive time
PU
11/15Gsk : BLOCK LISTING SIX MONTHLY RETURN - Form 6-K
PU
11/14Gsk : announces positive Phase IIa study results for a new first-in-class candidate medici..
PU
11/14GSK provides an update on Zejula (niraparib) US prescribing information
AQ
11/09Positive data for bepirovirsen from B-Clear phase IIb trial presented at American Assoc..
AQ
11/07GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory mult..
AQ
11/03Gsk : Q3 2022 results transcript
PU
11/03Gsk : Supplementary Prospectus
PU
11/03Gsk : EAGLE-2 and EAGLE-3 phase III trials for gepotidacin stopped early for efficacy foll..
PU
11/03Gsk : EAGLE-2 and EAGLE-3 phase III trials for gepotidacin stopped early for efficacy foll..
PU
11/02GSK's respiratory syncytial virus older adult vaccine candidate granted Priority Review..
AQ
11/02Glaxo : Q3 Earnings Snapshot
AQ
11/02Gsk : Q3 2022 results slides
PU
11/02Gsk : Q3 2022 results infographic
PU
10/31European Medicines Agency validates ViiV Healthcare's marketing authorisation applicati..
AQ
10/31GSK marketing authorisation application for respiratory syncytial virus older adult vac..
AQ
10/28GSK, MorphoSys Licensing Partner, Provides Update on ContRAst Phase III Program for Oti..
AQ
10/28Gsk : marketing authorisation application for respiratory syncytial virus older adult vacc..
PU
10/28Gsk : European Medicines Agency validates ViiV Healthcare's marketing authorisation applic..
PU
10/28Gsk : European Medicines Agency validates ViiV Healthcare's marketing authorisation applic..
PU
10/28Gsk : marketing authorisation application for respiratory syncytial virus older adult vacc..
PU
10/27GSK reports outcome from US FDA Advisory Committee meeting on daprodustat for anaemia o..
AQ
10/27GSK provides update on ContRAst phase III programme for otilimab in the treatment of mo..
AQ
10/26GSK regulatory submission accepted by Japanese regulator for respiratory syncytial viru..
AQ
10/25Gsk : ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigati..
PU
10/21Gsk : regulatory submission accepted by Japanese regulator for respiratory syncytial virus..
PU
10/21Gsk : regulatory submission accepted by Japanese regulator for respiratory syncytial virus..
PU
10/20GSK plc - New data show Shingrix can provide at least 10 years of protection against sh..
AQ
10/19Gsk : New data show Shingrix can provide at least 10 years of protection against shingles ..
PU
10/18Shigellosis Pipeline Analysis : 05+ Companies are Working to Improve the Treatment Space |..
AQ
10/18Rabies Infection Pipeline Analysis : 10+ Companies are Working to Improve the Treatment Sp..
AQ
10/18Gsk : announces expanded collaboration with Tempus in precision medicine to accelerate R&D
PU
10/18US approval of GSK's vaccine wins over investors amid Zantac battle
AQ
10/17US FDA approves Menveo in a new single-vial presentation to help prevent disease caused..
AQ
10/14Gsk : 2022 Q3 pre-announcement aide memoire (PDF - 462.7KB)
PU
10/14GSK's older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduc..
AQ
10/13Gsk ( '') Transaction Notification F : GSK plc (the 'Company') Transaction notification - ..
PU
10/13Gsk : older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reductio..
PU
10/12Gsk : to present updates on its industry-leading infectious disease portfolio at IDWeek 20..
PU
10/12Gsk : Transaction notification - Form 6-K
PU
10/12Malaria Pipeline Landscape Analysis of 15+ Companies by DelveInsight
AQ
10/11US FDA approves Boostrix for immunisation during pregnancy for the prevention of whoopi..
AQ
10/07Gsk ( '') Transaction Notification F : GSK plc (the 'Company') Transaction notification - ..
PU
10/07Gsk : Transaction notification - Form 6-K
PU
10/07ViiV Healthcare Announces Recipients of Largest Philanthropic Fund in the US Dedicated ..
AQ
10/05Gsk : announces positive headline results from PERLA, the phase II trial of Jemperli (dost..
PU
09/27Iain Mackay, Chief Financial Officer, to retire from GSK, Julie Brown appointed as succ..
AQ
09/26GSK plc - Iain Mackay, Chief Financial Officer, to retire from GSK, Julie Brown appoint..
AQ
09/23GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a la..
AQ
09/23Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA..
AQ
09/21Gsk : and Microsoft, in collaboration with the Centre for Health and Disease Studies, laun..
PU
09/21Positive results for Haleon after GSK split
AQ
09/20Gsk : launches Sustainable Procurement Programme for suppliers
PU
09/12GSK plc - Zejula shows durable and sustained long-term progression-free survival benefi..
AQ
09/09Glaxosmithkline : Zejula (niraparib) shows durable and sustained long-term progression-fre..
PU
09/07SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nir..
AQ
09/06WHO grants prequalification to GSK's Mosquirix - the first and only approved malaria va..
AQ
09/06Glaxosmithkline : WHO grants prequalification to GSK's Mosquirix
PU
09/01Glaxosmithkline : GSK to highlight the latest advances in cancer research from across its ..
PU
08/24Glaxosmithkline : GSK Board changes - Form 6-K
PU
08/24Glaxosmithkline : GSK Board changes
PU
08/17Statement : Zantac (ranitidine) U.S. litigation - Form 6-K
PU
08/17Glaxosmithkline : US FDA accepts New Drug Application for GSK's momelotinib for the treatm..
PU
08/17Glaxosmithkline : US FDA accepts new drug application for GSK's momelotinib for the treatm..
PU
08/16Statement : Zantac (ranitidine) U.S. litigation
PU
08/16Glaxosmithkline : GSK completes acquisition of Affinivax, Inc - Form 6-K
PU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on GSK PLC